Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $9.7 million.

  • 4D Molecular Therapeutics' Gains from Investment Securities rose 970.69% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 970.69%. This contributed to the annual value of $9.3 million for FY2024, which is 1331.1% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Gains from Investment Securities is $9.7 million, which was up 970.69% from $10.4 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Gains from Investment Securities high stood at $10.4 million for Q2 2025, and its period low was -$440000.0 during Q4 2022.
  • Its 5-year average for Gains from Investment Securities is $5.3 million, with a median of $5.5 million in 2022.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Gains from Investment Securities skyrocketed by 14118396.67% in 2021, and later tumbled by 19166.67% in 2022.
  • 4D Molecular Therapeutics' Gains from Investment Securities (Quarter) stood at $480000.0 in 2021, then plummeted by 191.67% to -$440000.0 in 2022, then soared by 879.77% to $3.4 million in 2023, then surged by 157.22% to $8.8 million in 2024, then grew by 9.71% to $9.7 million in 2025.
  • Its Gains from Investment Securities was $9.7 million in Q3 2025, compared to $10.4 million in Q2 2025 and $2.8 million in Q1 2025.